In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections | Zendy

Akira Watanabe | Zendy; Yutaka Tokue | Zendy; Hiroshi Takahashi | Zendy; Tohru Kikuchi | Zendy; Takao Kobayashi | Zendy; Kazunori Gomi | Zendy; Shigeru Fujimura | Zendy; Toshihiro Nukiwa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections

Author(s) -

Akira Watanabe,

Yutaka Tokue,

Hiroshi Takahashi,

Tohru Kikuchi,

Takao Kobayashi,

Kazunori Gomi,

Shigeru Fujimura,

Toshihiro Nukiwa

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.7.1767

Subject(s) - quinolone , microbiology and biotechnology , in vitro , bacteria , respiratory tract infections , antibiotics , respiratory system , medicine , biology , biochemistry , genetics

The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniae and was at least as active as the other quinolones against gram-negative pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research